Iryna Drozd
Theratechnologies (NASDAQ:THTX) has resubmitted its supplemental Biologics License Application for a simplified dosing formulation of its drug tesamorelin for the reduction of excess abdominal fat in patients with HIV and lipodystrophy.
The company said the new formulation is intended to